Literature DB >> 22930355

Sequence selectivity of azinomycin B in DNA alkylation and cross-linking: a QM/MM study.

Dhurairajan Senthilnathan1, Anbarasan Kalaiselvan, Ponnambalam Venuvanalingam.   

Abstract

Azinomycin B--a well-known antitumor drug--forms cross-links with DNA through alkylation of purine bases and blocks tumor cell growth. This reaction has been modeled using the ONIOM (B3LYP/6-31+g(d):UFF) method to understand the mechanism and sequence selectivity. ONIOM results have been checked for reliability by comparing them with full quantum mechanics calculations for selected paths. Calculations reveal that, among the purine bases, guanine is more reactive and is alkylated by aziridine ring through the C10 position, followed by alkylation of the epoxide ring through the C21 position of Azinomycin B. While the mono alkylation is controlled kinetically, bis-alkylation is controlled thermodynamically. Solvent effects were included using polarized-continuum-model calculations and no significant change from gas phase results was observed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22930355     DOI: 10.1007/s00894-012-1557-2

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  15 in total

1.  A Synthetic Azinomycin Analogue with Demonstrated DNA Cross-Linking Activity: Insights into the Mechanism of Action of this Class of Antitumor Agent The authors gratefully acknowledge the financial support provided by the CRC and the EPSRC. We are indebted to the EPSRC National Mass Spectrometry Centre for performing mass spectral measurements, and the EPSRC Chemical Database Service at Daresbury.1.

Authors: 
Journal:  Angew Chem Int Ed Engl       Date:  2000-10-02       Impact factor: 15.336

2.  DNA Cross-Linking Agents as Antitumor Drugs.

Authors:  Scott R. Rajski; Robert M. Williams
Journal:  Chem Rev       Date:  1998-12-17       Impact factor: 60.622

3.  Carzinophilin, a new tumor inhibitory substance produced by streptomyces. I.

Authors:  T HATA; F KOGA; Y SANO; K KANAMORI; A MATSUMAE; R SUGAWARA; T HOSHI; T SHIMA; S ITO; S TOMIZAWA
Journal:  J Antibiot (Tokyo)       Date:  1954-08       Impact factor: 2.649

4.  On the origin of the DNA sequence selectivity of the azinomycins.

Authors:  Rachel C LePla; Cyrille A S Landreau; Michael Shipman; George D D Jones
Journal:  Org Biomol Chem       Date:  2005-03-01       Impact factor: 3.876

5.  Molecular modeling of DNA cross-linking analogues based on the azinomycin scaffold.

Authors:  Stefano Alcaro; Francesco Ortuso; Robert S Coleman
Journal:  J Chem Inf Model       Date:  2005 May-Jun       Impact factor: 4.956

6.  Studies on the mechanism of action of azinomycin B: definition of regioselectivity and sequence selectivity of DNA cross-link formation and clarification of the role of the naphthoate.

Authors:  Robert S Coleman; Ronelito J Perez; Christopher H Burk; Antonio Navarro
Journal:  J Am Chem Soc       Date:  2002-11-06       Impact factor: 15.419

7.  Effect of carzinophillin on bacterial deoxyribonucleic acid: formation of inter-strand cross-links in deoxyribonucleic acid and their disappearance during post-treatment incubation.

Authors:  A Terawaki; J Greenberg
Journal:  Nature       Date:  1966-01-29       Impact factor: 49.962

8.  Azinomycins A and B, new antitumor antibiotics. III. Antitumor activity.

Authors:  S Ishizeki; M Ohtsuka; K Irinoda; K Kukita; K Nagaoka; T Nakashima
Journal:  J Antibiot (Tokyo)       Date:  1987-01       Impact factor: 2.649

9.  Si-E (E = N, O, F) bonding in a hexacoordinated silicon complex: new facts from experimental and theoretical charge density studies.

Authors:  Nikolaus Kocher; Julian Henn; Boris Gostevskii; Daniel Kost; Inna Kalikhman; Bernd Engels; Dietmar Stalke
Journal:  J Am Chem Soc       Date:  2004-05-05       Impact factor: 15.419

10.  Binding of organometallic ruthenium(II) anticancer compounds to nucleobases: a computational study.

Authors:  Christian Gossens; Ivano Tavernelli; Ursula Rothlisberger
Journal:  J Phys Chem A       Date:  2009-10-29       Impact factor: 2.781

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.